Fosun Health Capital
China's Biomissile secures $28m Series B
Suzhou-based Biomissile has raised CNY 200m (USD 28m) in a Series B funding round led by Kequan Capital. Existing investor Fosun Health Capital re-upped.
Suzhou-based Biomissile has raised CNY 200m (USD 28m) in a Series B funding round led by Kequan Capital. Existing investor Fosun Health Capital re-upped.